People In The News

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BioMarker Strategies has named Samuel Broder, Mark Velleca, and Paul Beresford to its board of directors. Broder was VP and CMO at Celera for a dozen years, and he is a former director of the National Cancer Institute. Velleca founded and was VP of CGI Pharmaceuticals. Beresford currently is VP of business development at Biodesix, and he formerly was VP of translational diagnostics at Ventana Medical Systems.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.